Updated:
Finch Therapeutics Group, Inc.
Finch Therapeutics Group, a clinical-stage microbiome company, was founded in 2017 by Flagship Pioneering and went public in 2021.
Finch Therapeutics Group, Inc.
Founding year: 2017. David Berry, a Flagship Pioneering partner, incubated Finch as a Flagship venture, naming Mark Smith as an early executive. Smith returned as CEO in 2023 after a prior stint, replacing Geoff von Maltzahn. Wealth originates from Flagship Pioneering's venture model, not a single-operator fortune. Strategy: Finch focuses on microbiome-based therapies for infectious and autoimmune conditions. Its lead candidate, CP101 (currently in Phase 3), targets recurrent C. difficile infection. The firm also runs a PRISM platform for biologic discovery, engaging partnerships with Takeda and others. Its capital mix includes public equity (via Nasdaq: FNCH), debt facilities, and milestone payments from collaboration deals. Geographic footprint is US-centered, with clinical sites nationwide. Scale: The firm went public in 2021 at around $600M market cap. Recent 10-K filings show a cash runway extending into mid-2025, with no new disclosed funding rounds since 2022. Team size is not publicly detailed beyond C-suite titles. No disclosed additional offices. No philanthropic arm is separated. Structural differentiator: Finch operates as a public company with a single-asset focus — CP101. That creates a binary payout structure: either the Phase 3 trial succeeds and the asset gets commercialized, or capital evaporates. The Flagship-originated shell makes governance effectively a venture-backed public biotech, not a family office or traditional asset manager.
General information
Firm type
other
Year founded
2017
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Somerville
Corporate office
Somerville, Massachusetts, United States
Principals
Mark Smith
Chief Executive Officer
David Berry
Board Member
Sector focus
Frequently asked questions
Who runs investment decisions at Finch Therapeutics?
CEO Mark Smith runs strategic and capital-allocation decisions, with board oversight from Flagship Pioneering and independent directors. The firm's public structure means CFO and board approve major capital raises or partnership terms (per SEC filings).
How does Finch source its therapeutic candidates?
Finch's PRISM platform screens human microbiome samples to identify bacterial consortia linked to therapeutic effects. CP101 was derived from a single donor's stool sample, and the firm uses data analytics to refine composition (per the firm's S-1 filing, 2021).
Is Finch structured as a family office or a biotech firm?
Finch is a publicly traded biotech (Nasdaq: FNCH) originally incubated by Flagship Pioneering. It is not a family office — it has no HNW or single-family capital base. The firm uses public equity and debt, not family trust funds.
Does Finch participate in fund commitments or only direct development?
Finch does not invest third-party capital. It is a development-stage company that raises equity and debt for its own pipeline. There is no fund structure or outside LP involvement.
What investment stages does Finch typically target?
Finch targets clinical-stage proof-of-concept for microbiome therapies, not early seed or venture rounds. Its key focus is Phase 3 registration trials and potential commercialization.
Which sectors does Finch explicitly avoid?
I don't have a reliable public source restricting Finch's sector focus beyond microbiome therapeutics. The firm does not disclose explicit avoidance areas.
How is Finch related to Flagship Pioneering?
Flagship Pioneering incubated Finch in 2017 and remains a significant shareholder and board representative (David Berry). Flagship's model is venture creation — Finch was spun out as a separate entity with independent management and board (per Flagship's portfolio listing).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: